公开(公告)号：US09944712B2

公开(公告)日：2018-04-17

申请号：US14403171

申请日：2013-05-30

Applicant: INNATE PHARMA

Inventor： Cécile Bonnafous ,  Laurent Gauthier ,  Yannis Morel ,  Carine Paturel ,  Ivan Perrot

IPC: A61K39/395 ,  C07K16/28 ,  A61K47/68 ,  C07K14/705 ,  A61K39/00

CPC classification number: C07K16/2896 ,  A61K39/3955 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: Disclosed herein are anti-TLR3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-TLR3 antibodies.

公开(公告)号：US20160347853A1

公开(公告)日：2016-12-01

申请号：US15204851

申请日：2016-07-07

Applicant: Innate Pharma

Inventor： Laurent Gauthier ,  Catherine Massacrier ,  Yannis Morel ,  Carine Paturel

IPC: C07K16/28 ,  A61K45/06 ,  A61K47/48 ,  A61K39/395

CPC classification number: C07K16/2896 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6849 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/54 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present invention relates to antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind TLR3, and that optionally further modulate, e.g. inhibit, signaling. The invention also relates to cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to diagnose, treat or prevent diseases, e.g. autoimmune diseases, inflammatory diseases and the like.

Abstract translation: 本发明涉及特异性结合TLR3的抗体（例如单克隆抗体），抗体片段及其衍生物，并且任选进一步调节，例如， 抑制信号。 本发明还涉及产生这种抗体的细胞; 制备此类抗体的方法; 抗体的片段，变体和衍生物; 包含它们的药物组合物; 使用抗体诊断，治疗或预防疾病的方法，例如， 自身免疫性疾病，炎症性疾病等。

公开(公告)号：US09828427B2

公开(公告)日：2017-11-28

申请号：US14924786

申请日：2015-10-28

Applicant: INNATE PHARMA

Inventor： Nicolas Anfossi ,  Laurent Gauthier ,  Yannis Morel ,  Alessandro Moretta ,  Silvia Parolini ,  Benjamin Rossi

IPC: A61K39/00 ,  A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  A61K45/06

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732

Abstract: The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sézary Syndrome.

公开(公告)号：US20150140000A1

公开(公告)日：2015-05-21

申请号：US14403171

申请日：2013-05-30

Applicant: INNATE PHARMA

Inventor： Cécile Bonnafous ,  Laurent Gauthier ,  Yannis Morel ,  Carine Paturel ,  Ivan Perrot

IPC: C07K16/28 ,  A61K47/48

CPC classification number: C07K16/2896 ,  A61K39/3955 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: Disclosed herein are anti-TLR3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-TLR3 antibodies.

Abstract translation: 本文公开了抗TLR3抗体以及制备和使用它们的方法。 抗体特别适用于使用抗TLR3抗体治疗自身免疫性或炎性疾病。